Sex hormone-binding globulin: biomarker and hepatokine?
de novo lipogenesis
hepatokine
metabolic disease
sex hormone–binding globulin
Journal
Trends in endocrinology and metabolism: TEM
ISSN: 1879-3061
Titre abrégé: Trends Endocrinol Metab
Pays: United States
ID NLM: 9001516
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
16
03
2021
revised:
19
04
2021
accepted:
04
05
2021
pubmed:
31
5
2021
medline:
1
3
2022
entrez:
30
5
2021
Statut:
ppublish
Résumé
Over the past decade, there have been important breakthroughs in our understanding of the regulation and function of sex hormone-binding globulin (SHBG). A recent genome-wide association and Mendelian randomization study has provided new insights at the population level. Thorough study of genetic variants affecting serum SHBG has identified de novo lipogenesis as one of the mechanistic links between the metabolic syndrome and reduced serum SHBG levels in humans. Furthermore, careful deduction of the Mendelian randomization results suggests a direct, causal role for SHBG in the pathogenesis of type 2 diabetes, as a hepatokine, in women. These findings prompt the development of SHBG-raising therapies as a means to prevent or treat disorders such as type 2 diabetes and polycystic ovary syndrome.
Identifiants
pubmed: 34052096
pii: S1043-2760(21)00117-X
doi: 10.1016/j.tem.2021.05.002
pii:
doi:
Substances chimiques
Biomarkers
0
Sex Hormone-Binding Globulin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
544-553Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors have no interests to declare.